CervoMed Inc./$CRVO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
- Ticker
- $CRVO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- Boston, United States
- Website
- www.cervomed.com
CervoMed Inc. Metrics
BasicAdvanced
$21M
-
-$2.60
-3.99
-
Price and volume
Market cap
$21M
Beta
-3.99
52-week high
$10.00
52-week low
$1.27
Average daily volume
341K
Financial strength
Current ratio
5.367
Quick ratio
4.931
Profitability
Gross margin (TTM)
-249,863.57%
Net profit margin (TTM)
-326,822.54%
Operating margin (TTM)
-335,925.29%
Management effectiveness
Return on assets (TTM)
-70.33%
Return on equity (TTM)
-131.52%
Valuation
Price to revenue (TTM)
1,725.441
Price to book
1.19
Price to tangible book (TTM)
1.19
Price to free cash flow (TTM)
-0.566
Free cash flow yield (TTM)
-176.66%
Free cash flow per share (TTM)
-2.42
Growth
Revenue change (TTM)
-99.86%
Earnings per share change (TTM)
-9.64%
3-year revenue growth (CAGR)
-87.67%
3-year earnings per share growth (CAGR)
-22.27%
What the Analysts think about CervoMed Inc.
Analyst ratings (Buy, Hold, Sell) for CervoMed Inc. stock.
Analyst projections of the future price of CervoMed Inc. stock.
CervoMed Inc. Financial Performance
Revenues and expenses
CervoMed Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
CervoMed Inc. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.